RU2010113569A - Производное бензохинона е3330 в комбинации с химиотерапевтическими агентами для лечения рака и ангиогенеза - Google Patents
Производное бензохинона е3330 в комбинации с химиотерапевтическими агентами для лечения рака и ангиогенеза Download PDFInfo
- Publication number
- RU2010113569A RU2010113569A RU2010113569/15A RU2010113569A RU2010113569A RU 2010113569 A RU2010113569 A RU 2010113569A RU 2010113569/15 A RU2010113569/15 A RU 2010113569/15A RU 2010113569 A RU2010113569 A RU 2010113569A RU 2010113569 A RU2010113569 A RU 2010113569A
- Authority
- RU
- Russia
- Prior art keywords
- specified
- agent
- cancer
- additional therapeutic
- pharmaceutically acceptable
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 11
- 201000011510 cancer Diseases 0.000 title claims abstract 9
- 230000033115 angiogenesis Effects 0.000 title claims abstract 3
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims abstract 8
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 101100452003 Caenorhabditis elegans ape-1 gene Proteins 0.000 claims abstract 4
- 230000000694 effects Effects 0.000 claims abstract 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims abstract 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract 3
- 229960004316 cisplatin Drugs 0.000 claims abstract 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract 3
- 229960005277 gemcitabine Drugs 0.000 claims abstract 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical group OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims abstract 3
- 229960001924 melphalan Drugs 0.000 claims abstract 3
- 229930002330 retinoic acid Natural products 0.000 claims abstract 3
- 229960003433 thalidomide Drugs 0.000 claims abstract 3
- 229960001727 tretinoin Drugs 0.000 claims abstract 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract 2
- 201000009273 Endometriosis Diseases 0.000 claims abstract 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims abstract 2
- 208000002260 Keloid Diseases 0.000 claims abstract 2
- 201000004681 Psoriasis Diseases 0.000 claims abstract 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims abstract 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims abstract 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims abstract 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims abstract 2
- 208000006673 asthma Diseases 0.000 claims abstract 2
- 210000000481 breast Anatomy 0.000 claims abstract 2
- 208000037976 chronic inflammation Diseases 0.000 claims abstract 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 208000035475 disorder Diseases 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims abstract 2
- 210000001117 keloid Anatomy 0.000 claims abstract 2
- 208000002780 macular degeneration Diseases 0.000 claims abstract 2
- 210000000496 pancreas Anatomy 0.000 claims abstract 2
- 210000002307 prostate Anatomy 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
1. Способ подавления физиологических нарушений, связанных с измененным ангиогенезом, включающий введение нуждающемуся субъекту эффективного количества агента, селективно ингибирующего окислительно-восстановительную активность Ape1/Ref-1. ! 2. Способ по п.1, где указанным агентом является Е3330 или его фармацевтически приемлемая соль. ! 3. Способ по п.1, где указанное нарушение выбрано из онкологического заболевания, сердечно-сосудистого заболевания, хронического воспалительного заболевания, ревматоидного артрита, диабетической ретинопатии, макулярной дегенерации, ретролентальной фиброплазии, идиопатического фиброза легких, острого респираторного дистресс-синдрома взрослых, астмы, эндометриоза, псориаза, келоидов и системного склероза. ! 4. Способ по п.3, где указанным нарушением является рак. ! 5. Способ по п.4, где указанным агентом является Е3330, или его фармацевтически приемлемая соль, или сольват. ! 6. Способ по п.5, где указанному субъекту вводится по меньшей мере один дополнительный терапевтический агент. ! 7. Способ по п.6, где указанный дополнительный терапевтический агент выбран из мелфалана, гемцитабина, цисплатина, метосиамина, талидомида и его производных и ретиноевой кислоты. !8. Способ подавления онкологического заболевания, включающий введение нуждающемуся субъекту эффективного количества агента, который селективно ингибирует окислительно-восстановительную активность Ape1/Ref-1. ! 9. Способ по п.8, где указанным агентом является Е3330 или его фармацевтически приемлемая соль. ! 10. Способ по п.8, где указанное онкологическое заболевание выбрано из опухолей молочной железы, простаты, поджелудочной железы, толсто�
Claims (15)
1. Способ подавления физиологических нарушений, связанных с измененным ангиогенезом, включающий введение нуждающемуся субъекту эффективного количества агента, селективно ингибирующего окислительно-восстановительную активность Ape1/Ref-1.
2. Способ по п.1, где указанным агентом является Е3330 или его фармацевтически приемлемая соль.
3. Способ по п.1, где указанное нарушение выбрано из онкологического заболевания, сердечно-сосудистого заболевания, хронического воспалительного заболевания, ревматоидного артрита, диабетической ретинопатии, макулярной дегенерации, ретролентальной фиброплазии, идиопатического фиброза легких, острого респираторного дистресс-синдрома взрослых, астмы, эндометриоза, псориаза, келоидов и системного склероза.
4. Способ по п.3, где указанным нарушением является рак.
5. Способ по п.4, где указанным агентом является Е3330, или его фармацевтически приемлемая соль, или сольват.
6. Способ по п.5, где указанному субъекту вводится по меньшей мере один дополнительный терапевтический агент.
7. Способ по п.6, где указанный дополнительный терапевтический агент выбран из мелфалана, гемцитабина, цисплатина, метосиамина, талидомида и его производных и ретиноевой кислоты.
8. Способ подавления онкологического заболевания, включающий введение нуждающемуся субъекту эффективного количества агента, который селективно ингибирует окислительно-восстановительную активность Ape1/Ref-1.
9. Способ по п.8, где указанным агентом является Е3330 или его фармацевтически приемлемая соль.
10. Способ по п.8, где указанное онкологическое заболевание выбрано из опухолей молочной железы, простаты, поджелудочной железы, толстого кишечника, шейки матки, герминогенных опухолей, глиомы взрослых и детей, остеосаркомы, рабдомиосаркомы, немелкоклеточного рака легких, лейкоза и множественной миеломы.
11. Способ по п.10, где указанным агентом является Е3330, или его фармацевтически приемлемая соль, или сольват.
12. Способ по п.11, где указанному субъекту вводят по меньшей мере один дополнительный терапевтический агент.
13. Способ по п.12, где указанный дополнительный терапевтический агент выбран из мелфалана, гемцитабина, цисплатина, талидомида и его производных и ретиноевой кислоты.
14. Способ по п.2, где указанному субъекту вводят по меньшей мере один дополнительный терапевтический агент.
15. Способ по п.14, где указанным дополнительным терапевтическим агентом является бевацизумаб.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97539607P | 2007-09-26 | 2007-09-26 | |
| US60/975,396 | 2007-09-26 | ||
| US98956607P | 2007-11-21 | 2007-11-21 | |
| US60/989,566 | 2007-11-21 | ||
| PCT/US2008/077210 WO2009042542A1 (en) | 2007-09-26 | 2008-09-22 | Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010113569A true RU2010113569A (ru) | 2011-11-10 |
| RU2510270C2 RU2510270C2 (ru) | 2014-03-27 |
Family
ID=39951652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113569/15A RU2510270C2 (ru) | 2007-09-26 | 2008-09-22 | Производное бензохинона е3330 в комбинации с химиотерапевтическими агентами для лечения рака и ангиогенеза |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9089605B2 (ru) |
| EP (4) | EP2203161B1 (ru) |
| JP (4) | JP5628674B2 (ru) |
| KR (2) | KR101572688B1 (ru) |
| AU (5) | AU2008304619C1 (ru) |
| BR (1) | BRPI0817293A2 (ru) |
| CA (2) | CA2700365C (ru) |
| ES (2) | ES2675951T3 (ru) |
| IL (1) | IL204675A0 (ru) |
| MX (1) | MX2010003315A (ru) |
| RU (1) | RU2510270C2 (ru) |
| WO (2) | WO2009042542A1 (ru) |
| ZA (1) | ZA201002246B (ru) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2203161B1 (en) * | 2007-09-26 | 2018-05-09 | Indiana University Research and Technology Corporation | Quinone derivatives, pharmaceutical compositions, and uses thereof |
| US11331294B2 (en) | 2007-09-26 | 2022-05-17 | Indiana University Research And Technology Corporation | Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer |
| US9567346B2 (en) * | 2010-10-29 | 2017-02-14 | Life Technologies Corporation | Biotin derivatives |
| US9517244B2 (en) | 2011-04-22 | 2016-12-13 | University Of Florida Research Foundation, Inc. | Therapeutic combinations for use in neoplasia |
| JP6109821B2 (ja) * | 2011-05-26 | 2017-04-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ａｐｅ１媒介疾患を処置するためのキノン化合物 |
| WO2012167122A1 (en) | 2011-06-03 | 2012-12-06 | Indiana University Research And Technology Corporation | Compounds, compositions and methods for treating oxidative dna damage disorders |
| WO2013021953A1 (ja) * | 2011-08-05 | 2013-02-14 | 帝人株式会社 | 縮合多環芳香族化合物、芳香族重合体、及び芳香族化合物の合成方法 |
| US9624235B2 (en) * | 2012-01-31 | 2017-04-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity |
| ES2689665T3 (es) | 2012-03-14 | 2018-11-15 | Indiana University Research And Technology Corporation | Compuestos y métodos para tratar la leucemia |
| WO2013180217A1 (ja) | 2012-05-30 | 2013-12-05 | 日本ゼオン株式会社 | 重合性化合物、重合性組成物、高分子、及び光学異方体 |
| CN104603165B (zh) | 2012-07-09 | 2017-04-26 | 日本瑞翁株式会社 | 聚合性化合物、聚合性组合物、高分子、光学各向异性体及聚合性化合物的制备方法 |
| US9995865B2 (en) | 2012-10-22 | 2018-06-12 | Zeon Corporation | Phase difference plate, circularly polarizing plate, and image display device |
| WO2015025793A1 (ja) | 2013-08-22 | 2015-02-26 | 日本ゼオン株式会社 | 重合性化合物、重合性組成物、高分子、及び光学異方体 |
| KR102315630B1 (ko) | 2013-10-31 | 2021-10-20 | 제온 코포레이션 | 중합성 화합물, 중합성 조성물, 고분자, 및 광학 이방체 |
| KR101612097B1 (ko) | 2015-01-07 | 2016-04-12 | 충남대학교산학협력단 | 아세틸화된 산화환원조절단백-1의 제조방법 및 이를 함유하는 유방암 예방 및 치료용 조성물 |
| CN107406769B (zh) | 2015-03-19 | 2021-01-29 | 日本瑞翁株式会社 | 液晶性组合物、相位差层的制造方法和圆偏振片 |
| WO2016186853A1 (en) * | 2015-05-21 | 2016-11-24 | Indiana University Research & Technology Corporation | Methods of targeting ape1/ref-1 to inhibit hypoxia signaling genes |
| JP6975040B2 (ja) | 2015-05-28 | 2021-12-01 | 日本ゼオン株式会社 | 円偏光分離フィルムの製造方法 |
| KR20170052345A (ko) * | 2015-11-04 | 2017-05-12 | 충남대학교산학협력단 | 환원형 산화환원조절단백-1를 함유하는 염증 예방 및 치료용 약학 조성물 |
| JPWO2017110638A1 (ja) | 2015-12-22 | 2018-10-11 | 日本ゼオン株式会社 | 液晶性組成物、液晶硬化層及びその製造方法、並びに、光学フィルム |
| US10669482B2 (en) | 2016-03-08 | 2020-06-02 | Zeon Corporation | Liquid crystal composition, liquid crystal cured layer, and method for producing said liquid crystal cured layer |
| EP3573606A4 (en) * | 2017-01-25 | 2020-11-25 | Indiana University Research and Technology Corporation | PROPHYLAXIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA |
| US20190160034A1 (en) * | 2017-03-20 | 2019-05-30 | Indiana University Research And Technology Corporation | Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer |
| CN110392850A (zh) | 2017-03-24 | 2019-10-29 | 日本瑞翁株式会社 | 液晶固化膜及其制造方法 |
| EP3605167A4 (en) | 2017-03-24 | 2020-12-09 | Zeon Corporation | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL HARDENED FILM AND METHOD FOR MANUFACTURING THEREOF |
| EP3440047A4 (en) * | 2017-04-17 | 2020-04-01 | Indiana University Research & Technology Corporation | PREVENTING AND REVERSING INFLAMMATION-INSPECTED DNA DAMAGE |
| WO2018232238A1 (en) * | 2017-06-16 | 2018-12-20 | Indiana University Research And Technology Corporation | Therapeutic agent for tuberous sclerosis complex (tsc) |
| CN111936459B (zh) * | 2018-02-08 | 2023-06-20 | 印第安纳大学研究与技术公司 | 通过新型ape1/ref-1抑制剂靶向于眼部疾病 |
| CN108440271A (zh) * | 2018-04-03 | 2018-08-24 | 中山大学 | 一种6-甲氧基萘嵌苯酮类化合物的制备方法 |
| JP2022513193A (ja) * | 2018-12-17 | 2022-02-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 消化管障害及びその症状の治療 |
| KR20240049212A (ko) * | 2021-04-30 | 2024-04-16 | 오큐파이어 파마, 인크. | 당뇨병성 망막병증 및 관련 병태의 치료 방법 및 조성물 |
| EP4587003A2 (en) | 2022-09-14 | 2025-07-23 | Opus Genetics, Inc. | Salts and esters of apx3330 and therapeutic uses thereof |
| WO2025147565A1 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Treatment of necrotizing enterocolitis and symptoms thereof |
| WO2025194083A1 (en) * | 2024-03-14 | 2025-09-18 | Opus Genetics, Inc. | Compositions comprising an apx3330 hemicalcium salt monohydrate and therapeutic uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3438998A (en) * | 1964-10-05 | 1969-04-15 | Research Corp | Antibiotic lambertellin and method for production |
| JPS51128932A (en) * | 1975-04-30 | 1976-11-10 | Takeda Chem Ind Ltd | Organic compounds |
| JPS58177934A (ja) * | 1982-04-13 | 1983-10-18 | Takeda Chem Ind Ltd | ベンゾキノン誘導体 |
| FI102273B1 (fi) * | 1989-09-11 | 1998-11-13 | Eisai Co Ltd | Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyttö |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| JPH07291859A (ja) * | 1994-04-28 | 1995-11-07 | Eisai Co Ltd | 転写因子活性阻害剤 |
| AU3386597A (en) * | 1996-06-11 | 1998-01-07 | Advanced Research And Technology Institute, Inc. | Methods and compositions for the use of apurinic/apyrimidinic endonucleases |
| US6406917B1 (en) * | 1996-06-11 | 2002-06-18 | Advanced Research And Technology Institute | Methods and compositions for the use of apurinic/apyrimidinic endonucleases |
| EP0813866A3 (en) * | 1996-06-17 | 1999-01-20 | Eisai Co., Ltd. | Therapeutic agent for joint diseases |
| FR2757860B1 (fr) * | 1996-12-27 | 1999-04-23 | Oxis International Sa | Composes organoselenies cycliques, leur preparation et leurs utilisations, notamment therapeutiques |
| US5849793A (en) | 1997-08-15 | 1998-12-15 | The Picower Institute For Medical Research | HIV matrix protein tyrosine position 29 pocket binders |
| NZ515711A (en) | 1999-06-24 | 2004-01-30 | Pharmacia Corp | Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation |
| CA2441228A1 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| JP4485744B2 (ja) * | 2001-04-05 | 2010-06-23 | トレント・ファーマシューティカルズ・リミテッド | 老化−関連及び糖尿病性血管性合併症のための複素環式化合物 |
| US20030229004A1 (en) * | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| WO2003090681A2 (en) * | 2002-04-24 | 2003-11-06 | Research Development Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
| WO2005000900A1 (en) * | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Treatment with anti-vegf antibodies |
| US20060024691A1 (en) * | 2004-03-25 | 2006-02-02 | Buck Institute For Age Research | Novel pathways in the etiology of cancer |
| EP2203161B1 (en) | 2007-09-26 | 2018-05-09 | Indiana University Research and Technology Corporation | Quinone derivatives, pharmaceutical compositions, and uses thereof |
-
2008
- 2008-09-22 EP EP08834585.5A patent/EP2203161B1/en active Active
- 2008-09-22 BR BRPI0817293-5A patent/BRPI0817293A2/pt not_active Application Discontinuation
- 2008-09-22 KR KR1020107008591A patent/KR101572688B1/ko not_active Expired - Fee Related
- 2008-09-22 JP JP2010527065A patent/JP5628674B2/ja active Active
- 2008-09-22 ES ES08834585.5T patent/ES2675951T3/es active Active
- 2008-09-22 MX MX2010003315A patent/MX2010003315A/es not_active Application Discontinuation
- 2008-09-22 US US12/679,828 patent/US9089605B2/en active Active
- 2008-09-22 EP EP08832991.7A patent/EP2203162B1/en active Active
- 2008-09-22 US US12/679,824 patent/US9040505B2/en active Active
- 2008-09-22 CA CA2700365A patent/CA2700365C/en active Active
- 2008-09-22 EP EP20178056.6A patent/EP3725309B1/en active Active
- 2008-09-22 EP EP17197372.0A patent/EP3299015A1/en not_active Withdrawn
- 2008-09-22 CA CA2700274A patent/CA2700274C/en active Active
- 2008-09-22 JP JP2010527064A patent/JP5646327B2/ja active Active
- 2008-09-22 WO PCT/US2008/077210 patent/WO2009042542A1/en not_active Ceased
- 2008-09-22 WO PCT/US2008/077213 patent/WO2009042544A1/en not_active Ceased
- 2008-09-22 RU RU2010113569/15A patent/RU2510270C2/ru not_active IP Right Cessation
- 2008-09-22 ES ES08832991.7T patent/ES2653855T3/es active Active
- 2008-09-22 KR KR1020157007066A patent/KR101689796B1/ko not_active Expired - Fee Related
- 2008-09-22 AU AU2008304619A patent/AU2008304619C1/en active Active
-
2010
- 2010-03-23 IL IL204675A patent/IL204675A0/en unknown
- 2010-03-30 ZA ZA2010/02246A patent/ZA201002246B/en unknown
-
2014
- 2014-07-11 JP JP2014143310A patent/JP2015017091A/ja active Pending
-
2015
- 2015-04-20 US US14/690,973 patent/US10058523B2/en active Active
- 2015-07-07 JP JP2015136288A patent/JP2015212293A/ja active Pending
- 2015-12-09 AU AU2015268612A patent/AU2015268612B2/en active Active
-
2017
- 2017-05-11 AU AU2017203131A patent/AU2017203131C1/en active Active
-
2018
- 2018-07-25 US US16/044,981 patent/US20180325853A1/en not_active Abandoned
- 2018-11-01 AU AU2018256605A patent/AU2018256605C1/en active Active
-
2019
- 2019-04-08 US US16/377,442 patent/US20190231728A1/en not_active Abandoned
-
2020
- 2020-01-28 AU AU2020200585A patent/AU2020200585A1/en not_active Abandoned
-
2022
- 2022-03-07 US US17/688,081 patent/US20220184016A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010113569A (ru) | Производное бензохинона е3330 в комбинации с химиотерапевтическими агентами для лечения рака и ангиогенеза | |
| JPWO2023190748A5 (ru) | ||
| PH12019501098A1 (en) | Pyrrolopyrimidines as cftr potentiators | |
| Swenson et al. | Prevention of acute mountain sickness by acetazolamide: as yet an unfinished story | |
| Egleton et al. | Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases | |
| US9212142B2 (en) | Niacin mimetics, and methods of use thereof | |
| JP2005527599A5 (ru) | ||
| Cottin | The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis | |
| HRP20210090T1 (hr) | Farmaceutski pripravak koji sadrži nikotinsku kiselinu i/ili nikotinamid i/ili triptofan za pozitivan uticaj na crijevnu mikrobiotu | |
| EP2584899B1 (en) | Niacin mimetics, and use thereof | |
| Martoni et al. | Prospective Phase II Study of Single-Agent Gemcitabine in Untreated Elderly Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer | |
| JP2009542581A5 (ru) | ||
| HRP20110763T1 (hr) | Makrolidni konjugati s protuupalnom aktivnošću | |
| SI2968313T1 (en) | Combination of medicines | |
| Jena | Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2 | |
| Gillies et al. | AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study | |
| JP2013209384A5 (ru) | ||
| Uddin et al. | The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates | |
| CN113082039B (zh) | 一种用于治疗索拉菲尼耐药肿瘤的组合物及其应用 | |
| Zhang et al. | The current scenario on anticancer activity of artemisinin metal complexes, hybrids, and dimers | |
| CN110755432A (zh) | 烟酰胺在制备治疗手足皮肤反应制剂中的应用 | |
| Halbertsma et al. | Hypercapnic acidosis attenuates the pulmonary innate immune response in ventilated healthy mice | |
| Shiah et al. | Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma | |
| CN114259566B (zh) | 一种基于破坏氧化还原平衡的抗肿瘤组合物及应用 | |
| Peters | Tiotropium bromide triple combination therapy improves lung function and decreases asthma exacerbations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190923 |